[Federal Register Volume 76, Number 250 (Thursday, December 29, 2011)]
[Notices]
[Page 81979]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-33421]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 10, 2011, Norac Inc., 
405 S. Motor Avenue, Azusa, California 91702-3232, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
------------------------------------------------------------------------

    With regard to Gamma Hydroxybutyric Acid (2010), 
Tetrahydrocannabinols (7370), and Methamphetamine (1105) only, the 
company manufactures these controlled substances in bulk solely for 
distribution within the United States to customers engaged in dosage-
form manufacturing.
    With regard to Nabilone (7379), the company presently manufactures 
a small amount of this controlled substance in bulk solely to conduct 
manufacturing internal process development. It is the company's 
intention that, when the manufacturing process is refined to the point 
that its Nabilone bulk product is available for commercial use, the 
company will export the controlled substance in bulk solely to 
customers engaged in dosage-form manufacturing outside the United 
States. The company is aware of the requirement to obtain a DEA 
registration as an exporter to conduct this activity.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 27, 2012.

    Dated: December 20, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-33421 Filed 12-28-11; 8:45 am]
BILLING CODE 4410-09-P